

Supplementary Tables

Disease activity and dropout in young persons with Juvenile Idiopathic Arthritis in transition of care: a longitudinal observational study

Supplementary Table I. Associations of several variables including location of care (transition, paediatric and adult patient group) with disease activity over time. For the dichotomised JADAS27 state of remission the multilevel logistic regression model is used, for the continuous variable DAS28 the multivariate mixed mode.

	JADAS27-remission patients in transition		JADAS27-remission all patients		DAS28 patients in transition		DAS28 all patients	
	Odds (95% CI)	<i>p</i>	Odds (95% CI)	<i>p</i>	Estimate (SE)	<i>p</i>	Estimate (SE)	<i>p</i>
Time-point to transfer visit	0.6 (0.29-1.07)	0.08	NA	NA	-0.09 (0.11)	0.44	NA	NA
gender (male vs. female)	NA	NA	0.9 (0.74-1.11)	0.34	NA	NA	-0.10 (0.04)	0.02*
subtype	0.7 (0.23-2.01)	0.48	0.6 (0.33-1.13)	0.11	-0.23 (0.23)	0.33	-0.27 (0.13)	0.04*
	1.4 (0.73-1.21)	0.33	1.1 (0.77-1.62)	0.57	-0.08 (0.13)	0.54	0.04 (0.08)	0.56
MTX (no use vs. use)	4.5 (1.98-10.41)	<0.01*	3.5 (2-10-5.83)	<0.01*	0.54 (0.19)	0.01*	0.36 (0.10)	<0.01*
biologics (no use vs. use)	1.4 (0.53-3.81)	0.30	1.7 (0.83-3.61)	0.14	0.31 (0.21)	0.16	0.27 (0.13)	0.03*
Location of treatment of care	NA	NA	1.4 (0.74-2.48)	0.32	NA	NA	0.09 (0.08)	0.26

*Significant at a *p*-level of <0.05.

Supplementary Table II. Same analyses as in Table II, in a sensitivity analysis using worst and best disease outcome for those patients who dropout (JADAS27-state of remission vs. active disease; JADAS27 ≤1.0 vs. JADAS27 >1.0).

Associations of several variables including location of care (transition, paediatric and adult patient group) with JADAS27-state of remission over time, multilevel logistic regression model is used.

	JADAS27-remission worst case scenario patients in transition		JADAS27-remission worst case scenario all patients		JADAS27-remission best case patients in transition		JADAS27 remission best case all patients	
	Odds (95% CI)	<i>p</i>	Odds (95% CI)	<i>p</i>	Odds (95% CI)	<i>p</i>	Odds (95% CI)	<i>p</i>
Time-point to transfer visit	0.9 (0.65-1.12)	0.25	NA	NA	0.9 (0.66-1.11)	0.24	NA	NA
gender (male vs. female)	NA	NA	0.9 (0.72-1.09)	0.25	NA	NA	0.9 (0.73-1.11)	0.33
subtype	0.7 (0.25-2.02)	0.52	0.7 (0.36-1.19)	0.17	0.5 (0.21-1.38)	0.20	0.5 (0.30-0.95)	0.03*
	1.3 (0.71-2.42)	0.40	1.1 (0.74-1.56)	0.70	1.3 (0.77-2.17)	0.33	1.1 (0.79-1.60)	0.50
MTX (no use vs. use)	4.5 (1.97-10.22)	<0.01*	3.3 (1.90-5.41)	<0.01*	4.8 (2.18-10.54)	0.00*	3.9 (2.34-6.37)	<0.01*
biologics (no use vs. use)	1.5 (0.53-3.53)	0.52	1.7 (0.88-3.61)	0.12	1.5 (0.61-3.84)	0.36	1.6 (0.83-3.27)	0.16
Location of treatment of care	NA	NA	1.4 (0.77-2.49)	0.28	NA	NA	1.3 (0.72-2.31)	0.38

*Significant at a *p*-level of <0.05.